Vijai Joseph

List of Publications by Year in Descending Order

142 papers	8,368 citations	47 h-index	89 g-index
155 ext. papers	10,917 ext. citations	9.7 avg, IF	4.48 L-index

#	Paper	IF	Citations
142	The context-specific role of germline pathogenicity in tumorigenesis. *Nature Genetics*, **2021**, 53, 1577-1585	36.3	6
141	Inherited TP53 Variants and Risk of Prostate Cancer. *European Urology*, **2021**,	10.2	4
140	Clonal hematopoiesis is associated with risk of severe Covid-19. *Nature Communications*, **2021**, 12, 5975	17.4	12
139	Sequencing at lymphoid neoplasm susceptibility loci maps six myeloma risk genes. *Human Molecular Genetics*, **2021**, 30, 1142-1153	5.6	
138	Novel ultra-rare exonic variants identified in a founder population implicate cadherins in schizophrenia. *Neuron*, **2021**, 109, 1465-1478.e4	13.9	8
137	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
136	Prevalence of Germline Alterations on Targeted Tumor-Normal Sequencing of Esophagogastric Cancer. *JAMA Network Open*, **2021**, 4, e2114753	10.4	4
135	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. *American Journal of Human Genetics*, **2021**, 108, 1190-1203	11	1
134	Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer. *Clinical Cancer Research*, **2021**, 27, 1997-2010	12.9	2
133	Genome-wide homozygosity and risk of four non-Hodgkin lymphoma subtypes. *Journal of Translational Genetics and Genomics*, **2021**, 5, 200-217	1.7	
132	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
131	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. *Nature Cancer*, **2021**, 2, 357-365	15.4	23
130	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
129	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. *Journal of the National Cancer Institute*, **2021**,	9.7	12
128	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. *British Journal of Cancer*, **2021**, 125, 1135-1145	8.7	0
127	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
126	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9

125	Cascading After Peridiagnostic Cancer Genetic Testing: An Alternative to Population-Based Screening. *Journal of Clinical Oncology*, **2020**, 38, 1398-1408	2.2	20
124	11p15.5 epimutations in children with Wilms tumor and hepatoblastoma detected in peripheral blood. *Cancer*, **2020**, 126, 3114-3121	6.4	11
123	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
122	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
121	Cancer Susceptibility Mutations in Patients With Urothelial Malignancies. *Journal of Clinical Oncology*, **2020**, 38, 406-414	2.2	31
120	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
119	A Rare Mutation Predominant in Ashkenazi Jews Confers Risk of Multiple Cancers. *Cancer Research*, **2020**, 80, 3732-3744	10.1	7
118	Mutation Rates in Cancer Susceptibility Genes in Patients With Breast Cancer With Multiple Primary Cancers. *JCO Precision Oncology*, **2020**, 4,	3.6	2
117	Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways. *Human Molecular Genetics*, **2020**, 29, 70-79	5.6	12
116	Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. *Human Mutation*, **2020**, 41, 103-109	4.7	11
115	Lipid Trait Variants and the Risk of Non-Hodgkin Lymphoma Subtypes: A Mendelian Randomization Study. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 1074-1078	4	4
114	Two truncating variants in FANCC and breast cancer risk. *Scientific Reports*, **2019**, 9, 12524	4.9	2
113	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
112	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. *Journal of Clinical Oncology*, **2019**, 37, 286-295	2.2	203
111	Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes. *European Journal of Human Genetics*, **2019**, 27, 824-828	5.3	1
110	Genetically Determined Height and Risk of Non-hodgkin Lymphoma. *Frontiers in Oncology*, **2019**, 9, 1539	5.3	1
109	Novel Common Genetic Susceptibility Loci for Colorectal Cancer. *Journal of the National Cancer Institute*, **2019**, 111, 146-157	9.7	67
108	Genetic overlap between autoimmune diseases and non-Hodgkin lymphoma subtypes. *Genetic Epidemiology*, **2019**, 43, 844-863	2.6	15

107	Toward automation of germline variant curation in clinical cancer genetics. *Genetics in Medicine*, **2019**, 21, 2116-2125	8.1	14
106	Understanding inherited risk in unselected newly diagnosed patients with endometrial cancer. *JCO Precision Oncology*, **2019**, 3,	3.6	2
105	Germline deletion of in familial acute lymphoblastic leukemia. *Blood Advances*, **2019**, 3, 1039-1046	7.8	13
104	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. *American Journal of Human Genetics*, **2019**, 104, 21-34	11	363
103	Discovery of common and rare genetic risk variants for colorectal cancer. *Nature Genetics*, **2019**, 51, 76-87	36.3	177
102	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. *Journal of the National Cancer Institute*, **2018**, 110, 1067-1074	9.7	103
101	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
100	High-depth whole genome sequencing of an Ashkenazi Jewish reference panel: enhancing sensitivity, accuracy, and imputation. *Human Genetics*, **2018**, 137, 343-355	6.3	16
99	Germline Lysine-Specific Demethylase 1 () Mutations Confer Susceptibility to Multiple Myeloma. *Cancer Research*, **2018**, 78, 2747-2759	10.1	32
98	HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. *Cancer Research*, **2018**, 78, 4086-4096	10.1	18
97	Germline mutations in children and adults with cancer. *Journal of Physical Education and Sports Management*, **2018**, 4,	2.8	20
96	Frequency of actionable cancer predisposing germline mutations in patients with lung cancers.. *Journal of Clinical Oncology*, **2018**, 36, 1504-1504	2.2	2
95	DNA damage repair (DDR) germline mutations in patients (Pts) with urothelial carcinoma (UC).. *Journal of Clinical Oncology*, **2018**, 36, 1516-1516	2.2	2
94	Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. *PLoS Genetics*, **2018**, 14, e1007111	6	20
93	Inherited mutations in breast cancer patients with and without multiple primary cancers.. *Journal of Clinical Oncology*, **2018**, 36, 1503-1503	2.2	
92	Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. *Nature Communications*, **2018**, 9, 4182	17.4	8
91	Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma. *JAMA Oncology*, **2018**, 4, 1228-1235	13.4	66
90	Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. *Nature Communications*, **2017**, 8, 14175	17.4	54

89	The contribution of pathogenic variants in breast cancer susceptibility genes to familial breast cancer risk. *Npj Breast Cancer*, **2017**, 3, 22	7.8	78
88	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
87	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
86	Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. *JCO Precision Oncology*, **2017**, 2017,	3.6	151
85	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
84	Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing. *JAMA - Journal of the American Medical Association*, **2017**, 318, 825-835	27.4	235
83	Integrative clinical genomics of metastatic cancer. *Nature*, **2017**, 548, 297-303	50.4	440
82	Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. *Lupus Science and Medicine*, **2017**, 4, e000187	4.6	10
81	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
80	Prospective assessment for pathogenic germline alterations (PGA) in pancreas cancer (PAC).. *Journal of Clinical Oncology*, **2017**, 35, 4102-4102	2.2	4
79	Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladder?. *International Journal of Clinical Pharmacology and Therapeutics*, **2017**, 55, 203-209	2	2
78	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
77	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. *Journal of Clinical Oncology*, **2016**, 34, e61-7	2.2	6
76	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
75	Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia. *Nature Communications*, **2016**, 7, 10933	17.4	70
74	Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. *Clinical Genitourinary Cancer*, **2016**, 14, 511-517	3.3	4
73	Germline Variants in Targeted Tumor Sequencing Using Matched Normal DNA. *JAMA Oncology*, **2016**, 2, 104-11	13.4	198
72	Genetically predicted longer telomere length is associated with increased risk of B-cell lymphoma subtypes. *Human Molecular Genetics*, **2016**, 25, 1663-76	5.6	39

71	Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. *Human Molecular Genetics*, **2016**, 25, 1203-14	5.6	20
70	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
69	Collaborative science in the next-generation sequencing era: a viewpoint on how to combine exome sequencing data across sites to identify novel disease susceptibility genes. *Briefings in Bioinformatics*, **2016**, 17, 672-7	13.4	5
68	A Germline Variant on Chromosome 4q31.1 Associates with Susceptibility to Developing Colon Cancer Metastasis. *PLoS ONE*, **2016**, 11, e0146435	3.7	1
67	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
66	Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. *New England Journal of Medicine*, **2016**, 375, 443-53	59.2	791
65	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
64	Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer. *American Journal of Human Genetics*, **2016**, 98, 801-817	11	86
63	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
62	Conflicting Interpretation of Genetic Variants and Cancer Risk by Commercial Laboratories as Assessed by the Prospective Registry of Multiplex Testing. *Journal of Clinical Oncology*, **2016**, 34, 4071-4078	2.2	110
61	A Recurrent ERCC3 Truncating Mutation Confers Moderate Risk for Breast Cancer. *Cancer Discovery* , **2016**, 6, 1267-1275	24.4	30
60	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
59	FANCM c.5791C>T nonsense mutation (rs144567652) induces exon skipping, affects DNA repair activity and is a familial breast cancer risk factor. *Human Molecular Genetics*, **2015**, 24, 5345-55	5.6	68
58	An analysis of the association between prostate cancer risk loci, PSA levels, disease aggressiveness and disease-specific mortality. *British Journal of Cancer*, **2015**, 113, 166-72	8.7	8
57	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
56	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
55	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
54	Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populations. *European Journal of Haematology*, **2015**, 95, 442-8	3.8	26

53	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
52	Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia. *PLoS Genetics*, **2015**, 11, e1005262	6	99
51	A genome-wide association study of marginal zone lymphoma shows association to the HLA region. *Nature Communications*, **2015**, 6, 5751	17.4	44
50	Prediction of breast cancer risk based on profiling with common genetic variants. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	324
49	Tissue-Specific Enrichment of Lymphoma Risk Loci in Regulatory Elements. *PLoS ONE*, **2015**, 10, e0139360	3.7	5
48	Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma. *Nature Genetics*, **2014**, 46, 1233-8	36.3	108
47	Genome-wide association study identifies five susceptibility loci for follicular lymphoma outside the HLA region. *American Journal of Human Genetics*, **2014**, 95, 462-71	11	74
46	Cancer genomics and inherited risk. *Journal of Clinical Oncology*, **2014**, 32, 687-98	2.2	100
45	Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins. *Nature Communications*, **2014**, 5, 4835	17.4	115
44	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
43	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
42	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
41	Variants at IRX4 as prostate cancer expression quantitative trait loci. *European Journal of Human Genetics*, **2014**, 22, 558-63	5.3	27
40	Genetic association analysis of ATP binding cassette protein family reveals a novel association of ABCB1 genetic variants with epilepsy risk, but not with drug-resistance. *PLoS ONE*, **2014**, 9, e89253	3.7	14
39	Genetic variation in DNA repair pathways and risk of non-Hodgkin lymphoma. *PLoS ONE*, **2014**, 9, e101685	3.7	12
38	COMPLEXO: identifying the missing heritability of breast cancer via next generation collaboration. *Breast Cancer Research*, **2013**, 15, 402	8.3	30
37	A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. *Nature Genetics*, **2013**, 45, 1226-1231	36.3	205
36	Major vault protein (MVP) gene polymorphisms and drug resistance in mesial temporal lobe epilepsy with hippocampal sclerosis. *Gene*, **2013**, 526, 449-53	3.8	14

35	Prevalence of HOXB13 mutation in a population of Ashkenazi Jewish men treated for prostate cancer. *Familial Cancer*, **2013**, 12, 597-600	3	8
34	Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. *Nature Genetics*, **2013**, 45, 868-76	36.3	147
33	Germline single nucleotide polymorphisms associated with response of urothelial carcinoma to platinum-based therapy: the role of the host. *Annals of Oncology*, **2013**, 24, 2414-21	10.3	10
32	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
31	A recessive founder mutation in regulator of telomere elongation helicase 1, RTEL1, underlies severe immunodeficiency and features of Hoyeraal Hreidarsson syndrome. *PLoS Genetics*, **2013**, 9, e1003695	6	85
30	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
29	Susceptibility loci associated with specific and shared subtypes of lymphoid malignancies. *PLoS Genetics*, **2013**, 9, e1003220	6	38
28	GABRG2, rs211037 is associated with epilepsy susceptibility, but not with antiepileptic drug resistance and febrile seizures. *Pharmacogenetics and Genomics*, **2013**, 23, 605-10	1.9	31
27	Assessment of SLX4 Mutations in Hereditary Breast Cancers. *PLoS ONE*, **2013**, 8, e66961	3.7	24
26	Saliva samples for genomic testing for preventive oncology: Improving the yield.. *Journal of Clinical Oncology*, **2013**, 31, e12555-e12555	2.2	
25	Transcriptional regulation and prostate cancer risk loci.. *Journal of Clinical Oncology*, **2013**, 31, 1554-1554	2.2	
24	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
23	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. *Cancer*, **2012**, 118, 493-9	6.4	71
22	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
21	Rare de novo germline copy-number variation in testicular cancer. *American Journal of Human Genetics*, **2012**, 91, 379-83	11	20
20	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
19	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
18	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49

17	995 ANALYSIS OF STATIN MEDICATION, GENETIC VARIATION AND PROSTATE CANCER OUTCOMES. *Journal of Urology*, **2011**, 185,	2.5	2
16	Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. *Breast Cancer Research and Treatment*, **2011**, 127, 479-87	4.4	15
15	Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. *Human Genetics*, **2011**, 130, 685-99	6.3	15
14	Genetic architecture of prostate cancer in the Ashkenazi Jewish population. *British Journal of Cancer*, **2011**, 105, 864-9	8.7	9
13	Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2011**, 20, 4693-706	5.6	66
12	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
11	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
10	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
9	Susceptibility loci associated with prostate cancer progression and mortality. *Clinical Cancer Research*, **2010**, 16, 2819-32	12.9	64
8	Genome-wide association studies of cancer predisposition. *Hematology/Oncology Clinics of North America*, **2010**, 24, 973-96	3.1	33
7	A locus for juvenile myoclonic epilepsy maps to 2q33-q36. *Human Genetics*, **2010**, 128, 123-30	6.3	10
6	The role of PAK-1 in activation of MAP kinase cascade and oncogenic transformation by Akt. *Oncogene*, **2009**, 28, 2365-9	9.2	48
5	Protective and susceptibility effects of hSKCa3 allelic variants on juvenile myoclonic epilepsy. *Journal of Medical Genetics*, **2005**, 42, 439-42	5.8	7
4	Absence of GABRA1 Ala322Asp mutation in juvenile myoclonic epilepsy families from India. *Journal of Genetics*, **2003**, 82, 17-21	1.2	11
3	Genetic association analysis of KCNQ3 and juvenile myoclonic epilepsy in a South Indian population. *Human Genetics*, **2003**, 113, 461-3	6.3	13
2	Clinical characteristics of a South Indian cohort of juvenile myoclonic epilepsy probands. *Seizure: the Journal of the British Epilepsy Association*, **2003**, 12, 490-6	3.2	33
1	Combining genome-wide studies of breast, prostate, ovarian and endometrial cancers maps cross-cancer susceptibility loci and identifies new genetic associations		2